Invivyd, Inc. Faces Delisting Concerns

Ticker: IVVD · Form: 8-K · Filed: Apr 25, 2025 · CIK: 1832038

Invivyd, INC. 8-K Filing Summary
FieldDetail
CompanyInvivyd, INC. (IVVD)
Form Type8-K
Filed DateApr 25, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

TL;DR

Invivyd's on the chopping block - might get delisted soon.

AI Summary

Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of April 21, 2025. The company, incorporated in Delaware, is in the biological products sector and is headquartered in Waltham, MA.

Why It Matters

This filing indicates potential issues with Invivyd's compliance with stock exchange listing requirements, which could impact its stock's tradability and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial health.

Key Numbers

Key Players & Entities

FAQ

What specific listing rule or standard has Invivyd, Inc. failed to satisfy?

The filing does not specify the exact listing rule or standard that Invivyd, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy has been issued.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on April 21, 2025.

What was Invivyd, Inc.'s former name?

Invivyd, Inc.'s former name was Adagio Therapeutics, Inc.

Where are Invivyd, Inc.'s principal executive offices located?

Invivyd, Inc.'s principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.

What is the filing date of this 8-K report?

This 8-K report was filed on April 25, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 25, 2025 regarding Invivyd, Inc. (IVVD).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing